Chemical Patent Strategy

Markush claims are the cornerstone of chemical patent strategy: DEFINITION: a Markush group is a claim format that defines a chemical compound by a core structure with variable groups listed as alternatives; the claim covers all compounds within the defined structural framework; ORIGIN: developed in Ex parte Markush (USPTO 1924); now standard worldwide; FORMAT: 'A compound of formula R-CO-NR1R2, wherein R is selected from the group consisting of methyl, ethyl, propyl, and phenyl; R1 is selected from the group consisting of hydrogen and C1-C4 alkyl; and R2 is...'; BREADTH: a single Markush claim can potentially cover millions (or billions) of specific compounds; the claim covers every compound defined by any combination of the listed variables; PRIOR ART SCOPE: a Markush claim is anticipated by prior art if: a single prior art compound falls within the claim (every combination is covered; if one prior art compound is within the formula, the claim is anticipated for that species); for obviousness, if the prior art discloses a closely related compound, the specific compound within the claim may be obvious; WRITTEN DESCRIPTION FOR MARKUSH CLAIMS: the specification must describe the claimed Markush group with adequate written description; representative species spanning the genus; working examples showing that the compounds as a class have the claimed utility; structural similarity linking all Markush members; ENABLEMENT: the POSITA must be able to make and use all claimed compounds without undue experimentation; for large Markush groups, some examples must be worked; HOW TO STRUCTURE A MARKUSH CLAIM HIERARCHY: Claim 1: broadest Markush genus (all possible substituents within the structural class); Dependent Claims 2-10: progressively narrower Markush subgroups; Claim 11: narrowest — the specific lead compound most likely to be commercially developed; this hierarchy ensures fallback protection even if the broadest claims are narrowed in prosecution or invalidated.

Selection inventions are an important claim type when the broad class was already known: DEFINITION: a selection invention is a patent covering a specific subset (selection) from a previously disclosed larger genus, where the selection has unexpected properties or advantages over the rest of the genus; EXAMPLE: prior art discloses 'compounds of formula X where R is any alkyl group'; the inventor selects R = n-butyl and discovers this specific compound has unexpectedly superior binding affinity, stability, or safety compared to other alkyl variants; the selection of n-butyl is patentable if the advantage is truly unexpected and substantial; REQUIREMENTS: (1) the selected subset must not be individually disclosed in the prior art (if the prior art specifically described n-butyl, no selection invention); (2) the subset must have unexpected properties that would not be predictable from the prior art genus; (3) the advantages must be described in the patent application and preferably supported by comparative data; COMPARATIVE DATA: selection inventions are supported by comparative examples showing that the selected subset performs significantly better than other members of the genus; courts and patent offices require the comparative data to show that the advantage is: not obvious from the genus disclosure; genuinely surprising (not merely incremental); attributable to the structural selection made; INTERPLAY WITH OBVIOUS TO TRY: KSR (S.Ct. 2007) 'obvious to try' analysis is applied to chemical selection inventions; if the prior art teaches that compounds in the genus have a range of properties and routine optimization would lead to the selected subset, the selection may be obvious; unexpected results are the key secondary consideration; PHARMACEUTICAL RELEVANCE: selection inventions are common in pharmaceutical patent strategy for enantiomers (active vs. inactive stereoisomers); specific polymorphs; specific salt forms.

Process patents cover synthesis routes and manufacturing methods for chemical compounds: SCOPE OF COMPOSITION vs. PROCESS: COMPOSITION-OF-MATTER CLAIMS: cover the chemical compound itself regardless of how it is made; the broadest protection; cannot be designed around by using a different synthesis route; PROCESS CLAIMS: cover a specific method of making the compound; can be designed around by using a different synthesis route to make the same compound; WHEN PROCESS PATENTS ARE VALUABLE: when composition claims are unavailable (compound is in the prior art but the process is novel and non-obvious); when the process provides substantial cost or quality advantages; when the process enables large-scale manufacturing not previously possible; for natural products: you cannot patent a naturally occurring compound but you can patent a synthetic process to make it; PRODUCT-BY-PROCESS CLAIMS: 'a compound made by the process of reacting A with B at 100°C for 2 hours'; this claim covers the compound as made by this specific process; IMPORTANT LIMITATION: if the same compound can be made by a different process, a product-by-process claim does NOT cover the compound made by the alternative process (Atlantic Thermoplastics v. Faytex Corp.); the compound itself must be novel — a product-by-process claim is invalid if the compound was known before, even if the process is new; PROCESS PATENT INFRINGEMENT: more difficult to detect and prove than composition infringement; products in the US market: a product made abroad by a patented process can be imported, but the process patent owner can obtain exclusion at the ITC (§ 337); 35 U.S.C. § 271(g): importing or selling a product made abroad by a patented process infringes; IMPORTATION: chemical process patents are particularly important for chemicals manufactured overseas and imported into the US.

Stereoisomers and polymorphs are important sources of patentable chemical innovations: STEREOISOMERS — ENANTIOMERS: many pharmaceutical compounds have a chiral center (asymmetric carbon); the two mirror-image forms (enantiomers: R and S; or (+) and (-)) may have different biological activity; PATENTABILITY OF ENANTIOMERS: if the prior art only disclosed the racemic mixture (50/50 mix of R and S), the individual enantiomers are separately patentable if they have unexpected properties relative to the racemate; EXAMPLE: Lexapro (escitalopram) was patented as the active (S)-enantiomer of Celexa (citalopram; racemic); the enantiomer was novel over the racemate and had advantages in tolerability; DIASTEREOMERS AND OTHER ISOMERS: geometric isomers (cis/trans); structural isomers; these can each be independently patented if they have novel and non-obvious properties; POLYMORPHISM: many crystalline compounds can exist in multiple crystal forms (polymorphs) with different physical properties; PATENTABILITY OF POLYMORPHS: a new polymorph of a known compound is patentable if it is novel and non-obvious; the new polymorph typically must have an unexpected or advantageous property: better solubility; better bioavailability; higher stability; easier manufacturability; different melting point (easier processing); EVIDENCE OF UNEXPECTED PROPERTIES: provide comparative data showing the polymorph's advantages; data must be in the application or submitted during prosecution; STRATEGIC IMPORTANCE FOR PHARMACEUTICALS: manufacturers use enantiomer and polymorph patents as 'evergreening' strategies to extend effective exclusivity beyond the original compound patent; these are legitimate patents as long as the advantages are genuine and non-obvious; ANHYDROUS vs. HYDRATE: another source of polymorph-like patents; salt forms: different acid addition salts of a basic drug compound each have different physical properties and may be separately patentable.

Chemical patent portfolio strategy requires a layered, hierarchical approach: LAYER 1 — COMPOSITION CLAIMS (BROADEST): Markush group claim covering the entire structural class of compounds; all reasonable substituents; all reasonable combinations; this is the core patent that competitors must design around; LAYER 2 — SUB-GENUS CLAIMS: narrower Markush groups focusing on the most commercially important subclass; the preferred substituents; the subgenera with the best properties; LAYER 3 — SPECIFIC COMPOUND CLAIMS: individual compound claims for the lead compound(s) being commercialized; these are easiest to enforce and most directly protect the product; LAYER 4 — PROCESS CLAIMS: synthesis routes for the key compounds; specific conditions (temperature; pressure; catalysts; solvents) that provide commercial advantages; these protect the manufacturing know-how; LAYER 5 — FORMULATION CLAIMS: specific formulations (excipients; delivery systems; concentrations) that provide product performance advantages; harder to design around than the compound itself for competitors who want to copy the product; LAYER 6 — USE CLAIMS: specific applications of the compound; method-of-use patents covering the specific application being commercialized; important for pharmaceuticals (indication-specific protection) and specialty chemicals (specific industrial use); FILING STRATEGY: file broad Markush genus claim first with all variants; file provisional with all available data; identify lead compounds early; file continuation applications as new data becomes available; add new examples to continuations (within the original disclosure); FREEDOM TO OPERATE: for new chemical series, conduct FTO on: existing Markush claims in the same chemical space; process patents for synthesis routes; formulation patents in the relevant field; DEFENSIVE PUBLICATION: for unpatentable intermediates or side products, defensive publication creates prior art against competitors who might try to patent the same compounds.